相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra et al.
BRITISH JOURNAL OF CANCER (2018)
TGFβ1 Genetic Variants Predict Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy
Ye Tao et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.
Yulia Vugmeyster et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
p16, HPV, and Cetuximab: What Is the Evidence?
James A. Bonner et al.
ONCOLOGIST (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma
Vandana Singh Kushwaha et al.
CANCER BIOLOGY & THERAPY (2015)
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
Jill Gilbert et al.
ORAL ONCOLOGY (2015)
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Han Sang Kim et al.
CLINICAL CANCER RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).
Veena Shankaran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TGFβ Receptor 1: An Immune Susceptibility Gene in HPV-Associated Cancer
Chaya Levovitz et al.
CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
V. Gregoire et al.
ANNALS OF ONCOLOGY (2010)
Association of TGF-β1 Genetic Variants with HPV16-positive Oropharyngeal Cancer
Xiaoxiang Guan et al.
CLINICAL CANCER RESEARCH (2010)
Total Exposure and Exposure Rate Effects for Alcohol and Smoking and Risk of Head and Neck Cancer: A Pooled Analysis of Case-Control Studies
Jay H. Lubin et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Transforming growth factor-β and the immune response:: Implications for anticancer therapy
Stephen H. Wrzesinski et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
A. Dimitrios Colevas
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
